300 related articles for article (PubMed ID: 25652561)
21. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
Zink RC; Huang Q; Zhang LY; Bao WJ
Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
[TBL] [Abstract][Full Text] [Related]
22. Suspected adverse reactions, 2007.
Dyer F; Spagnuolo-Weaver M; Coolees S; Tait A
Vet Rec; 2008 Jul; 163(3):69-72. PubMed ID: 18702197
[No Abstract] [Full Text] [Related]
23. Propensity score methods in drug safety studies: practice, strengths and limitations.
Wang J; Donnan PT
Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
[No Abstract] [Full Text] [Related]
24. [Adverse drug reactions reporting is helping "non substituable" prescription!].
Jacquot J; Bagheri H; Montastruc JL
Therapie; 2014; 69(3):259-61. PubMed ID: 24927508
[TBL] [Abstract][Full Text] [Related]
25. Reported adverse drug events in infants and children under 2 years of age.
Moore TJ; Weiss SR; Kaplan S; Blaisdell CJ
Pediatrics; 2002 Nov; 110(5):e53. PubMed ID: 12415059
[TBL] [Abstract][Full Text] [Related]
26. European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?
Bleumink GS; in't Veld BA; Stricker BH
Pharmacoepidemiol Drug Saf; 2001; 10(4):339-40. PubMed ID: 11760496
[No Abstract] [Full Text] [Related]
27. Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.
Hoffman KB; Demakas A; Erdman CB; Dimbil M; Doraiswamy PM
BMJ; 2013 Jul; 347():f4656. PubMed ID: 23881998
[No Abstract] [Full Text] [Related]
28. Alert systems for post-marketing surveillance of adverse drug reactions.
Praus M; Schindel F; Fescharek R; Schwarz S
Stat Med; 1993 Dec; 12(24):2383-93. PubMed ID: 8134741
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
[TBL] [Abstract][Full Text] [Related]
30. Emergency department visits by children and adolescents for antipsychotic drug adverse events.
Hampton LM; Daubresse M; Chang HY; Alexander GC; Budnitz DS
JAMA Psychiatry; 2015 Mar; 72(3):292-4. PubMed ID: 25588054
[No Abstract] [Full Text] [Related]
31. Reporting of adverse events to MedWatch.
Piazza-Hepp TD; Kennedy DL
Am J Health Syst Pharm; 1995 Jul; 52(13):1436-9. PubMed ID: 7671043
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
[TBL] [Abstract][Full Text] [Related]
33. Signal selection and follow-up in pharmacovigilance.
Meyboom RH; Lindquist M; Egberts AC; Edwards IR
Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
[TBL] [Abstract][Full Text] [Related]
34. The FDA Sentinel Initiative - An Evolving National Resource.
Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
[No Abstract] [Full Text] [Related]
35. Role of postmarketing surveillance in contemporary medicine.
Woodcock J; Behrman RE; Dal Pan GJ
Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
[TBL] [Abstract][Full Text] [Related]
36. Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project.
Scott HD; Thacher-Renshaw A; Rosenbaum SE; Waters WJ; Green M; Andrews LG; Faich GA
JAMA; 1990 Apr; 263(13):1785-8. PubMed ID: 2313850
[TBL] [Abstract][Full Text] [Related]
37. Adverse reactions: know the risks.
Shepherd M
Nurs Times; 2011 Apr 5-11; 107(13):20. PubMed ID: 21678719
[No Abstract] [Full Text] [Related]
38. [Farmacovigilance: the way towards a safer drug use].
Dobrić S
Vojnosanit Pregl; 2007 Apr; 64(4):229-30. PubMed ID: 17580530
[No Abstract] [Full Text] [Related]
39. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy.
Juhlin K; Ye X; Star K; Norén GN
Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1119-29. PubMed ID: 23832706
[TBL] [Abstract][Full Text] [Related]
40. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
